scholarly journals Immunogold labeling method for Mycobacterium leprae-specific phenolic glycolipid in glutaraldehyde-osmium-fixed and Araldite-embedded leprosy lesions.

1989 ◽  
Vol 37 (4) ◽  
pp. 455-462 ◽  
Author(s):  
J Boddingius ◽  
H P Dijkman
Keyword(s):  
Specific Antigen ◽  
Mycobacterium Leprae ◽  
Immunogold Labeling ◽  
Host Cells ◽  
Cell Mediated Immunity ◽  
Leprosy Patients ◽  
Skin Biopsies ◽  
Labeling Method ◽  
Multibacillary Leprosy ◽  
Swine Serum

Phenolic glycolipid (PGL)-I, a Mycobacterium leprae-specific antigen currently used for serodiagnosis of preclinical leprosy, has thus far not been localized subcellularly in leprosy bacilli and their host cells. In this study, we developed an immunogold-labeling technique for qualitative identification of PGL-I sites in glutaraldehyde-osmium-fixed and Araldite-embedded M. leprae and host macrophages in human skin biopsies. Such "hard-fixed," plastic-embedded skin and nerve biopsies from patients with varying cell-mediated immunity to leprosy are amply available worldwide. Our method involves etching of plastic sections with H2O2, incubation with swine serum to eliminate nonspecific labeling, and long (22 hr) incubation at room temperature with monoclonal antibodies to PGL-I. Gold labeling was seen predominantly on cell walls of M. leprae, in vacuolar spaces of bacillated phagolysosomes, and occasionally on the cytoplasm and cell membrane of M. leprae. Host macrophage cytoplasm was labeled very infrequently. This technique allows studies on possibly persisting antigenic PGL-I in multibacillary leprosy patients during or after multidrug therapy. The method may also prove useful for subcellular localization of specific bacterial lipids in other mycobacterial diseases, including tuberculosis.

The Response to Chemotherapy of Serum Mycobacterium Leprae-Specific Antigen in Multibacillary Leprosy Patients

1991 ◽  
Vol 44 (6) ◽  
pp. 702-708 ◽  
Author(s):  
Paul W. Roche ◽  
Kapil Dev Neupane ◽  
Wim J. Theuvenet ◽  
Sang-Nae Cho ◽  
Warwick J. Britton ◽  
...  
Keyword(s):  
Specific Antigen ◽  
Mycobacterium Leprae ◽  
Response To Chemotherapy ◽  
Leprosy Patients ◽  
Multibacillary Leprosy

Recent Advancement in the Diagnosis and Treatment of Leprosy

2018 ◽  
Vol 18 (18) ◽  
pp. 1550-1558
Author(s):  
Muhammad Aamir ◽  
Asma Sadaf ◽  
Sehroon Khan ◽  
Shagufta Perveen ◽  
Afsar Khan
Keyword(s):  
Vitamin D ◽  
Drug Treatment ◽  
Mycobacterium Leprae ◽  
Neglected Diseases ◽  
Specific Drug ◽  
Genetic Studies ◽  
Vitamin D Receptors ◽  
Micro Rnas ◽  
Leprosy Patients ◽  
Skin Biopsies

Background: Many of the tropical diseases are neglected by the researchers and medicinal companies due to lack of profit and other interests. The Drugs for Neglected Diseases initiative (DNDi) is established to overcome the problems associated with these neglected diseases. According to a report published by the WHO, leprosy (Hansen's disease) is also a neglected infectious disease. Methods: A negligible amount of advancements has been made in last few decades which includes the tools of diagnosis, causes, treatment, and genetic studies of the bacterium (Mycobacterium leprae) that causes leprosy. The diagnosis of leprosy at earlier stages is important for its effective treatment. Recent studies on vitamin D and its receptors make leprosy diagnosis easier at earlier stages. Skin biopsies and qPCR are the other tools to identify the disease at its initial stages. Results: Until now a specific drug for the treatment of leprosy is not available, therefore, Multi-Drug Therapy (MDT) is used, which is hazardous to health. Besides Mycobacterium leprae, recently a new bacterium Mycobacterium lepromatosis was also identified as a cause of leprosy. During the last few years the genetic studies of Mycobacterium leprae, the role of vitamin D and vitamin D receptors (VDR), and the skin biopsies made the treatment and diagnosis of leprosy easier at early stages. The studies of micro RNAs (miRNAs) made it easy to differentiate leprosy from other diseases especially from tuberculosis. Conclusion: Leprosy can be distinguished from sarcoidosis by quantitative study of reticulin fibers present in skin. The treatment used until now for leprosy is multi-drug treatment. The complete genome identification of Mycobacterium leprae makes the research easy to develop target specified drugs for leprosy. Rifampicin, identified as a potent drug, along with other drugs in uniform multi-drug treatment, has a significant effect when given to leprosy patients at initial stages. These are effective treatments but a specific drug for leprosy is still needed to be identified. The current review highlights the use of modern methods for the identification of leprosy at its earlier stages and the effective use of drugs alone as well as in combination.

Analysis of the Myeloid-Derived Suppressor Cells and Annexin A1 in Multibacillary Leprosy and Reactional Episodes

2020 ◽  
Author(s):  
Amilcar Sabino Damazo ◽  
Stephanni Figueiredo da Silva ◽  
Leticia Rossetto da Silva Cavalcante ◽  
Ezequiel Angelo Fonseca Junior ◽  
Joselina Maria da Silva ◽  
...  
Keyword(s):  
Suppressor Cells ◽  
Suppressor Cell ◽  
Mycobacterium Leprae ◽  
Histopathological Analysis ◽  
Annexin A1 ◽  
Myeloid Derived Suppressor Cells ◽  
Myeloid Derived Suppressor Cell ◽  
Leprosy Patients ◽  
Multibacillary Leprosy

Abstract Background: Leprosy is a chronic infectious disease caused by Mycobacterium leprae. Patients have distinct clinical forms, and host´s immunological response regulate those manifestations. In this work, the presence of the myeloid-derived suppressor cell and the regulatory protein annexin A1 is described in patients with multibacillary leprosy and with type 1 and 2 reactions. Methods: Patients were submitted to skin biopsy for histopathological analysis to obtain bacilloscopic index. Immunofluorescence was used to detect myeloid-derived suppressor cells and annexin A1.Results: The data demonstrated that the presence of granulocytic and monocytic myeloid-derived suppressor cells in leprosy patients. The high number of monocytic myeloid-derived suppressor cells were observed in lepromatous leprosy and type 2 reactional patients with Bacillus Calmette–Guérin (BCG) vaccination scar. The presence of annexin A1 was observed in all myeloid-derived suppressor cells. In particularly, the monocytic myeloid-derived suppressor cell in the lepromatous patients has higher levels of this protein when compared to the reactional patients. This data suggest that the higher expression of this protein may be related to regulatory response against a severe infection, contributing to anergic response. In type 1 reactional patients, the expression of annexin A1 was reduced. Conclusions: Myeloid-derived suppressor cell are present in leprosy patients and annexin A1 might be regulated the host response against Mycobacterium leprae.

scholarly journals Powerful Bactericidal Activity of Moxifloxacin in Human Leprosy

2008 ◽  
Vol 52 (9) ◽  
pp. 3113-3117 ◽  
Author(s):  
Fe Eleanor F. Pardillo ◽  
Jasmin Burgos ◽  
Tranquilino T. Fajardo ◽  
Eduardo Dela Cruz ◽  
Rodolfo M. Abalos ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Bactericidal Activity ◽  
Mycobacterium Leprae ◽  
Skin Lesions ◽  
Definite Improvement ◽  
Highly Effective ◽  
Leprosy Patients ◽  
Multibacillary Leprosy

ABSTRACT In a clinical trial of moxifloxacin in eight multibacillary leprosy patients, moxifloxacin proved highly effective. In all trial patients, a single 400-mg dose of moxifloxacin resulted in significant killing (P ≤ 0.006) of Mycobacterium leprae, ranging from 82% to 99%, with a mean of 91%. In all instances, no viable bacilli were detected with an additional 3 weeks of daily therapy, this observed rapid bactericidal activity being matched previously only by rifampin. On moxifloxacin therapy, skin lesions cleared exceedingly rapidly with definite improvement observed consistently after eight doses and progressive resolution continuing for the 56 days of the trial. Side effects, toxicities, and laboratory abnormalities were mild, not requiring discontinuation of therapy.

scholarly journals Mycobacterium leprae is identified in the oral mucosa from paucibacillary and multibacillary leprosy patients

2014 ◽  
Vol 20 (1) ◽  
pp. 59-64 ◽  
Author(s):  
M.A.M. Morgado de Abreu ◽  
A.M. Roselino ◽  
M. Enokihara ◽  
S. Nonogaki ◽  
L.E. Prestes-Carneiro ◽  
...  
Keyword(s):  
Oral Mucosa ◽  
Mycobacterium Leprae ◽  
Leprosy Patients ◽  
Multibacillary Leprosy

scholarly journals Clinical profile and deformities in leprosy patients: a record based study

2020 ◽  
Vol 6 (2) ◽  
pp. 156
Author(s):  
Anita Sanker ◽  
Sandhya George ◽  
Sindhu Chunangat Bhaskaramenon
Keyword(s):  
Public Health Problem ◽  
Mycobacterium Leprae ◽  
Clinical Profile ◽  
Current Status ◽  
Age Group ◽  
Medical College ◽  
Tribal Area ◽  
Leprosy Patients ◽  
Multibacillary Leprosy

<p class="abstract"><strong>Background:</strong> Leprosy is a chronic disease caused by <em>Mycobacterium leprae</em>, infectious in some cases, and affecting the peripheral nervous system, skin and certain other tissues. Even though leprosy was declared eliminated as a public health problem in India on December 2005, new cases of leprosy continue to appear. Hence a study on clinical profile and deformities in all leprosy cases registered in the last 5 years was done to know the current status of leprosy in this area.</p><p class="abstract"><strong>Methods: </strong>This was a retrospective record-based study of leprosy cases done at Government Medical College, Manjeri, for a period of 5 years from October 2014 to September 2019.<strong></strong></p><p class="abstract"><strong>Results:</strong> 42 cases from the record were included in the study. Maximum cases belonged to the age group of 31 to 40 and males were more than females. 81% of the patients were multibacillary leprosy (MB) and 8 cases belonged to paucibacillary (PB) leprosy. Four child cases were registered as PB cases. Mostly encountered clinical diagnosis was borderline tuberculoid leprosy (23 out of 42) and two had type 1 reaction. Seven patients had deformity of which two had grade 2 deformity and rest had grade 1 deformity.</p><p><strong>Conclusions:</strong> One patient who presented with grade 2 deformity and type 1 reaction was from tribal area indicating low awareness about leprosy among them. More number of cases in the multibacillary group and presence of child cases and deformities reinforces the need for strict surveillance to eradicate leprosy. </p>

scholarly journals Analysis of the myeloid-derived suppressor cells and annexin A1 in multibacillary leprosy and reactional episodes

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Stephanni Figueiredo da Silva ◽  
Leticia Rossetto da Silva Cavalcante ◽  
Ezequiel Angelo Fonseca Junior ◽  
Joselina Maria da Silva ◽  
José Cabral Lopes ◽  
...  
Keyword(s):  
Suppressor Cells ◽  
Suppressor Cell ◽  
Mycobacterium Leprae ◽  
Histopathological Analysis ◽  
Annexin A1 ◽  
Myeloid Derived Suppressor Cells ◽  
Myeloid Derived Suppressor Cell ◽  
Leprosy Patients ◽  
Multibacillary Leprosy

Abstract Background Leprosy is a chronic infectious disease caused by Mycobacterium leprae. Patients have distinct clinical forms, and the host´s immunological response regulate those manifestations. In this work, the presence of the myeloid-derived suppressor cell and the regulatory protein annexin A1 is described in patients with multibacillary leprosy and with type 1 and 2 reactions. Methods Patients were submitted to skin biopsy for histopathological analysis to obtain a bacilloscopic index. Immunofluorescence was used to detect myeloid-derived suppressor cells and annexin A1. Results The data demonstrated that the presence of granulocytic and monocytic myeloid-derived suppressor cells in leprosy patients. A high number of monocytic myeloid-derived suppressor cells were observed in lepromatous leprosy and type 2 reactional patients. The presence of annexin A1 was observed in all myeloid-derived suppressor cells. In particular, the monocytic myeloid-derived suppressor cell in the lepromatous patients has higher levels of this protein when compared to the reactional patients. This data suggest that the higher expression of this protein may be related to regulatory response against a severe infection, contributing to anergic response. In type 1 reactional patients, the expression of annexin A1 was reduced. Conclusions Myeloid-derived suppressor cell are present in leprosy patients and annexin A1 might be regulated the host response against Mycobacterium leprae.

Naegleria fowleri:Location of a Specific Antigen Using an Immunogold Labeling Method

1997 ◽  
Vol 85 (3) ◽  
pp. 299-302
Author(s):  
Olivier Sparagano ◽  
Christine Guicher ◽  
Simone Peyrol
Keyword(s):  
Specific Antigen ◽  
Immunogold Labeling ◽  
Labeling Method
Sign in / Sign up

Export Citation Format

Share Document